Background: Deep vein thrombosis (DVT) is a potentially progressive disease with complex clinical sequelae. The clinical practice guidelines of the American College of Chest Physicians (ACCP) recommend various treatments for all patients with objectively proven DVT. This study retrospectively compares enoxaparin with CDT on treatment efficacy and safety and the evolution of acute proximal DVT in the lower limbs. Methods: This study comprised 53 patients with acute proximal DVT, who received either CDT followed by intravenous unfractionated heparin (UFH) or adjusted subcutaneous low-molecular-weight heparin (LMWH) (enoxaparin) for 7e14 days. Warfarin was administered to all patients for at least 6 months. The study endpoints included the evolution of DVT and treatment efficacy and safety, which were assessed with frequent duplex ultrasounds, plethysmography, and venography. The mean duration of the follow-up was 15.2 months. Results: In the CDT group, patency of the iliofemoral vein segment was observed in 42.3% of the patients after 1 week ( p < 0.001) and in 69.2% after 6 months. In the control group, patency was present in 15.4% of the patients after 3 months and in 38.5% after 6 months ( p ¼ 0.05). Femoral venous obstruction was found in 30.8% of CDT patients and in 61.5% of the control group ( p ¼ 0.05). Furthermore, femoral venous insufficiency was present in 46.2% of the CDT group and 53.9% of the control group after 6 months ( p ¼ 0.587). After 12 months, postthrombotic syndrome (PTS) was found in 19.2% of the CDT patients compared to 50% of the LMWH group ( p ¼ 0.04). Conclusion: Duplex ultrasound analysis of thrombus progression is useful for assessing the treatment of a patient with acute proximal DVT. In this study, patients undergoing CDT experienced higher thrombus resolution and early recanalization of their veins, which may preserve venous function and further prevent development of post-thrombotic syndrome.
Introduction
Deep vein thrombosis (DVT) is a potentially progressive disease with complex clinical sequelae, such as pulmonary embolism (PE) and post-thrombotic syndrome (PTS). Although the clinical practice guidelines of the American College of Chest Physicians (ACCP) recommend treatment with anticoagulation [i.e., either adjusted subcutaneous low-molecular-weight heparin (LMWH) or intravenous unfractionated heparin (UFH) followed by oral anticoagulation] for all patients with objectively proven DVT, LMWH is as clinically effective as UFH and presents fewer hemorrhagic complications. 1e4 However, this therapy does not directly promote thrombus dissolution to reduce the thrombus burden, nor does it preserve venous valve function and protect against PTS manifestations, which can appear several months to years after the acute episode of DVT. Recent studies have found that 49e60% of patients develop PTS within 2 years after initial treatment of proximal DVT. 5, 6 Recently, catheter-directed intrathrombus thrombolysis (CDT) has been recommended as a new therapy for DVT because it can reduce the thrombus load rapidly, relieve DVT symptoms promptly, maintain venous valve function, and reduce recurrence of DVT. 7, 8 Consequently, clinical use of thrombolytic agents has received significant attention because of the impressive thrombolysis achieved with CDT. A large study has demonstrated that CDT can achieve a complete or partial thrombolysis rate of at least 83% compared to treatment with anticoagulation alone. 8e10,20 The present study retrospectively compared enoxaparin with CDT for efficacy and safety and the evolution of acute proximal DVT in the lower limbs.
Methods
Approval from an institutional review board of Taipei Veterans General Hospital was obtained for this retrospective study, which included a waiver of informed consent. This retrospective study involved 53 patients who had experienced symptoms of acute proximal DVT for <14 days. They received either CDT followed by intravenous UFH or body-weight-adjusted subcutaneous enoxaparin for 7e14 days. Warfarin was administered to all patients for at least 6 months between January 2009 and October 2010. The patients comprised 26 women and 27 men, with a mean age of 62 AE 16.2 years (range: 34e84 years). Twenty-seven of the patients were treated with CDT (i.e., the CDT group) followed by UFH, and26 were treated with LMWH alone (i.e., the control group). The primary symptoms were limb swelling, discoloration, pain, and venous claudication in the majority of patients. Duplex sonography was first used to diagnose DVT and then to confirm the extent of DVT among the patients. The evolution of DVT was analyzed according to the thrombus score (TS) classification modified by Haenen et al and Porter et al. 11, 12 The mean duration of the follow-up was 15.2 months.
Patient characteristics and clinical parameters are shown in Table 1 . The relevant medical history, physical examinations, and diagnostic test results, including those from phlebography and color duplex ultrasound, were reviewed for all patients. Patients recruited for this study were required to have acute proximal DVT of the lower limbs. Exclusion criteria comprised severe anemia, severe renal failure, active internal bleeding, thrombocytopenia, bilateral DVT, and contraindications to thrombolytic treatment such as hemorrhagic stroke or other intracranial disease, major surgery within 30 days, intractable hypertension, and prolonged traumatic cardiopulmonary resuscitation.
Antithrombotic therapy and thrombolytic techniques
Antithrombotic therapy was administered according to the clinical practice guidelines of the ACCP. We provided patients with LMWH for 7e14 days followed by oral warfarin for at least 6 months, while ensuring they presented an international normalized ratio (INR) of 2e3. 1 The CDT protocol of this study was modified from the CaVenT Study (catheter-directed venous thrombolysis in acute iliofemoral vein thrombosis trial). 8 Informed consent was obtained from each patient who was willing to undergo CDT.
Before performing the CDT procedure, the antithrombotic medication of patients was temporarily not given to obtain an INR of <1.5. At the beginning of the CDT procedure, an intravenous bolus of 3000e5000 U of UFH was administered to obtain an activated clotting time of >200 s.
Briefly, percutaneous entry was achieved either through the lesser saphenous vein or the popliteal vein under ultrasound guidance. After the lesser saphenous vein was punctured, a 5-F or 6-F introducer sheath was inserted into the thrombosed vessel over a guide wire. Venography was performed to determine the extent of the thrombus. The guide wire and catheter were advanced above the proximal part of the thrombus. Then, appropriate multiside-hole infusion catheters were exchanged and secured in place. After the procedure, CDT was initiated with urokinase. The urokinase solution was continuously infused at a dose of 600e1200 U/kg/h over 48e72 h. The dosage of urokinase was adjusted according to the fibrinogen and hemoglobin levels and platelet counts. During CDT therapy, UFH was simultaneously administered via the sheath at a low dose of 5e10 U/kg/h. The activated partial thromboplastin time (aPTT) was maintained at 1.5e2.0 times greater than the control levels.
Patients' blood pressure, pulse, and the puncture site were checked four times daily. Hemoglobin and fibrinogen levels and platelet counts were measured daily. aPTT was examined twice daily. After the completion of CDT, systemic intravenous UFH was administered continuously to maintain an aPTT ratio 1.5e2.5 times greater than the control levels. Simultaneously, warfarin was administered and overlapped with UFH treatment for 4e5 days until an INR of 2e3 was achieved on 2 consecutive days. Elastic bandages or graduated elastic compression stockings were provided to all patients. Additionally, ambulation was initiated as soon as possible.
Safety and efficacy outcome measures
The study endpoints were DVT evolution and treatment safety and efficacy outcomes. These endpoints were assessed via clinical findings, and vascular laboratory instruments at pre-established times (i.e. baseline, 7 days, 1 month, 3 months, and 6 months). During the treatment, all patients were assessed for liver function, renal function, fibrinogen, prothrombin time, aPTT, D-dimer, and blood and platelet counts.
The safety outcome calculated the occurrence of bleeding and serious adverse events such as pulmonary embolism and death. Major bleeding was defined as obvious bleeding, such as intracranial bleeding, gastrointestinal bleeding, and retroperitoneal hematomas, which resulted in either hemodynamic instability, a blood transfusion of >2 U, surgery, or death. All other bleeding events were considered minor episodes.
The efficacy outcomes included early and immediate iliofemoral venous patency, valvular competence, recanalization of occluded veins, thrombus progression or resolution, recurrent DVT, and PTS. The development of DVT and the assessment of efficacy outcomes were conducted using duplex ultrasound and either plethysmography or venography at preestablished times (i.e., baseline, 7 days, 1 month, 3 months, 6 months, and 12 months).
Color Doppler ultrasound was performed by vascular physicians and experienced technicians. The evolution of DVT was analyzed according to the thrombus score (TS) classification modified by Haenen et al and Porter et al. 11, 12 The standardized definitions of the degree of thrombosis, vein segment classifications (i.e., external iliac, common femoral, proximal and distal femoral, popliteal, and great saphenous veins), and scores for the degree of venous obstruction (i.e., 0 ¼ open vein free of thrombus; 1 ¼ partially occluded vein with a flow Doppler signal; and 2 ¼ completely occluded vein with no flow signal) were determined. In each leg, TS before and after thrombolysis was calculated by summing the TS of the six vein segments (TS total ). ATS total increase indicated DVT progression, whereas decreased TS total indicated regression (i.e., complete lysis or incomplete lysis). When TS total remained the same at follow-up, no changes in DVT were considered.
Venous insufficiency was also evaluated with Doppler ultrasound, and a valvular reflux >0.5 s was set as valve incompetence of the involved segment. 13 Venous outflow (VO) resistance was assessed using air plethysmography. A tourniquet (10e12 cm wide) was placed at the thigh segment and inflated to 80 mmHg. Volume increased to a new plateau. The tourniquet was then deflated suddenly, and the VO curve was recorded. The outflow fraction at 1 s (OF 1 ) was the VO expressed as a percentage of the total venous volume. An OF 1 >38% was considered clinically to indicate the absence of any functional obstruction; 30e38% indicated moderate obstruction; and <28% indicated severe obstruction.
14 After 12 months, PTS was assessed using the Villalta scale, 15 which included five symptoms (pain, cramps, heaviness, pruritus, and paresthesia) and six indications (edema, skin induration, hyperpigmentation, venous ectasia, redness, and pain during calf compression). Each indication or symptom was rated as either 0 (absent), 1 (mild), 2 (moderate), or 3 (severe). Points were then summed to determine the total score. A total score >15 or a venous ulcer indicated severe PTS, and a total score of 5e14 was considered mild to moderate PTS.
The venous registry index was used to classify DVT patients receiving CDT treatment. The degree of thrombolysis was determined from the differences between the pre-and post-thrombolysis thrombus of each involved segment using various interval venography. Complete thrombolysis (grade III) was when clot lysis of 95e100% was achieved, partial thrombolysis (grade II) was when clot lysis of 50e90% was achieved, and minimal or no thrombolysis (grade I) was when clot lysis of <50% was achieved. 16 
Statistical analysis
Continuous variables were reported as means AE standard deviations. Baseline demographic and clinical characteristics between the CDT and anticoagulant groups were compared using a two-sided ManneWhitney test. Differences between the anticoagulant and CDT groups were determined using Fisher's exact test for dichotomous variables. A p value <0.05 was considered statistically significant. All statistical analyses were performed using SPSS software.
Results
From January 2009 to October 2010, we recruited 53 patients with acute proximal DVT of less than 14 days, who received either CDT followed by intravenous UFH or only body-weight-adjusted subcutaneous enoxaparin. The baseline demographics and clinical characteristics of these patients were compared and are shown in Table 1 . No significant differences existed between the two treatment groups Table 2 .
DVT evolution
During the follow-up period, changes over time in the number of thrombosed vein segments were assessed with duplex ultrasound for all 53 patients, at pre-established times (i.e., baseline, and after 7 days, 1 month, 3 months, and 6 months). Therefore, according to the mean TS total score, the cumulative incidence of recanalization of thrombosed vein segments increased steadily in both groups, but was more prominent in the CDT group (Fig. 3) . Recanalization was found in 89% of the CDT group at 3 months and 93.2% at 6 months, whereas 37.4% of the control group experienced recanalization at 3 months and 54% at 6 months. Furthermore, early recanalization was more prominent in the CDT group after 1 week to 3 months of treatment ( p < 0.001) (Fig. 3) .
In the CDT group, additional venography testing was performed to evaluate the degree of thrombolysis after CDT treatment. Complete lysis was found in 12 patients, and partial lysis (grade II) was found in 15 patients following the completion of CDT treatment. These results were comparable to the ultrasonographic findings. Furthermore, three of the 12 patients with complete lysis received percutaneous angioplasty and Wallstents for stenotic lesions in the left common iliac veins (Fig. 2) .
Efficacy outcomes at 1 week, 1 month, 3 months, and 6 months
In the control group, four patients experienced thrombus progression; thus, LMWH therapy was prolonged by >10 days for these cases. During the follow-up period, three cases of recurrent DVT occurred; specifically, one case occurred in the CDT group, and the other two in the control group (Table 3) . Of these three patients with recurrent DVT, two experienced malignancies, and one experienced anal bleeding.
In the CDT group, patency of the iliofemoral vein segment was observed in 42.3% of the patients after 1 week and 69.2% after 6 months. However, in the control group, patency was observed in only 15.4% of the patients after 3 months and 38.5% after 6 months. Significant differences existed between the CDT and the control groups for the patency of the iliofemoral vein segment ( Fig. 1 and Tables 3 and 4) .
Femoral venous obstruction was found in only 30.8% of CDT patients compared to 61.5% of the control group after 6months ( p ¼ 0.05). Femoral venous insufficiency was observed in 46.2% of the CDT group and 53.9% of the control group; no significant differences were found after 6 months ( p ¼ 0.782) ( Table 4) .
The degree of PTS after 12 months is shown in Table 3 . After 12 months, PTS was found in 19.2% of the CDT group compared to 50% of the control group; significant differences were also observed ( p ¼ 0.04) ( Table 4 ).
Safety outcomes
During therapy, two patients in the CDT group did not receive complete thrombolytic treatment because they experienced bleeding complications. Of these two patients, one (female) reported episodes of oral bleeding related to tonsil abscess rupture, and consequently required a blood transfusion of 2 U packed red blood cells. The other patient (male) suffered anal bleeding, and subsequently required surgical treatment for hemorrhoids. Therefore, these two patients showed ineffective thrombolysis. However, no significant differences were observed between the two groups for bleeding events during this study (Table 5 ).
Discussion
After initial treatment, patients' symptoms of acute DVT, such as leg swelling, tightness, and pain, typically disappeared rapidly. In our ultrasonographic observations, the following factors were primarily responsible for the immediate resolution of these symptoms: (1) recovery of VO (i.e., recanalization) and (2) the development of bypassing collateral veins. As observed by Thomas et al, 17 the resolution of these symptoms is primarily the result of bypassing collateral veins, which are typically detected around the occluded vein segment immediately following LMWH treatment. In the present study, patients undergoing CDT experienced rapid resolution of their symptoms, which primarily resulted from effective thrombolysis and early vein recanalization (Figs. 1 and 3) .
A review of the relevant literature suggests that CDT and LMWH substantially influence thrombus regression and prevent recurrent DVT. 8,12,19e21,23 In the present study, recanalization occurred in 74.7% and 89% of the CDT group after 1 week and 3 months of treatment, respectively. However, only 37.4% and 54% of the control group experienced recanalization at 3 and 6 months, respectively. Furthermore, CDT has been shown to be effective in achieving short-and intermediate-term venous patency.
8e10,18e20 These series on CDT reported a 6-month patency of 60e85% compared to 69.2% in the present study. Thus, CDT appears to achieve early recanalization and superior venous patency in an acute setting compared to anticoagulants alone. However, the Fig. 1 . Cumulative incidence of complete lysis (iliofemoral patency) in both the CDT and LMWH groups. Bleeding diathesis Hemorrhagic stroke Major surgery &1 month Severe hypertension with persistent systolic blood pressure S180 mmHG or diastolic blood pressure S100 mmHg Severe renal failure e estimated creatinine clearance <25 ml min
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Primary or metastatic central nervous system malignancy relationships between early recanalization and long-term functional venous outcomes have yet to be clarified. This was also one of the study limitations.
Numerous studies have shown that CDT and LMWH have significant effects on the regression of thrombus and the prevention of recurrent DVT and subsequent PTS. 9, 10, 18, 19, 21, 22, 24 These series have reported a thrombus regression rate of w58.3% for enoxaparin and <50% for UFH after 6 months. In the present study, the regression rate was 54% for enoxaparin and 93.2% for CDT treatment after 6 months ( Figs. 1 and 3) . Specifically, after 12 months, the CDT group had a significantly higher number of patients with a comparatively favorable degree of PTS ( p ¼ 0.04) ( Table 4) . This indicates that CDT may reduce PTS development because of its superior thrombus resolution and early recanalization.
From a clinical practice and follow-up perspective, venography is a relatively invasive and inconvenient procedure. Therefore, during treatment follow-up, all patients underwent duplex ultrasound, which is a valid alternative to venography for predicting the presence of thrombosis in patients with acute proximal DVT. 23 A few studies have discussed the clinical and ultrasonographic differences between CDT and LMWH treatment among patients with proximal DVT of the lower limbs.
Thus, a head-to-head analysis comparing CDT and LMWH should provide substantial information of DVT evolution and of the treatment efficacy and safety.
In the present study, CDT was successfully performed in most patients (n ¼ 25). The incidence of major bleeding events was similar to that reported by other studies. 8, 20 Only two patients experienced major bleeding events that required blood transfusions, and both recovered rapidly without sequelae. Thus, CDT treatment appears to be as safe as anticoagulation (Table 5) . Additionally, three patients in the CDT group received angioplasty and Wallstents for stenotic lesions in the common iliac veins. The number of patients in this group was limited, therefore, no significant differences were observed between the two study groups. Nevertheless, in addition to the treatment for proximal DVT, the use of ancillary treatments, specifically angioplasty and stents, should be Fig. 3 . Recanalization of the thrombosed veins of patients in both the CDT and the LMWH groups developed according to the mean total thrombus score. Table 3 Noninvasive assessments of vein patency after 1 week and 1, 3, and 6 months after treatment.
Endpoints
Anticoagulation group considered necessary for enhancing short-and long-term venous patency. Large prospective randomized studies that focus on the short-and long-term outcomes of adjuvant angioplasty and stents in patients have yet to be conducted.
In conclusion, our short-term results suggest that CDT treatment is as safe as anticoagulation and provides greater thrombus resolution and earlier recanalization, which may preserve venous function and further prevent PTS. In addition, duplex ultrasound analysis of thrombus progression is useful for assessing the treatment of patients with acute proximal DVT. 
